tiprankstipranks
Avalo Therapeutics, Inc. (AVTX)
:AVTX
US Market

Avalo Therapeutics (AVTX) Financial Statements

Compare
906 Followers

Avalo Therapeutics Financial Overview

Avalo Therapeutics's market cap is currently $70.33M. The company's EPS TTM is $-161.416; its P/E ratio is ―; Avalo Therapeutics is scheduled to report earnings on March 27, 2025, and the estimated EPS forecast is $-1.18. See an overview of income statement, balance sheet, and cash flow financials.
Dec 24Dec 23Dec 22Dec 21Dec 20
Income Statement
Total Revenue$ 441.00K$ 1.92M$ 18.05M$ 5.40M$ 6.70M
Gross Profit$ -26.83M$ 640.00K$ 14.62M$ 3.91M$ 6.40M
Operating Income$ -68.51M$ -23.44M$ -37.44M$ -82.13M$ -26.95M
EBITDA$ -68.51M$ -27.95M$ -37.29M$ -80.50M$ -45.45M
Net Income$ -35.13M$ -31.54M$ -41.66M$ -84.35M$ -64.38M
Balance Sheet
Cash & Short-Term Investments$ 134.55M$ 7.42M$ 13.17M$ 54.59M$ 18.92M
Total Assets$ 150.73M$ 20.99M$ 33.37M$ 80.21M$ 43.76M
Total Debt$ 568.00K$ 537.00K$ 19.42M$ 32.83M$ 426.35K
Net Debt$ -133.98M$ -6.88M$ 6.24M$ -21.75M$ -18.49M
Total Liabilities$ 17.70M$ 13.69M$ 44.28M$ 57.13M$ 19.19M
Stockholders' Equity$ 133.03M$ 7.30M$ -10.91M$ 23.08M$ 24.56M
Cash Flow
Free Cash Flow$ -49.06M$ -30.84M$ -26.85M$ -71.00M$ -40.60M
Operating Cash Flow$ -49.06M$ -30.68M$ -26.75M$ -70.89M$ -40.54M
Investing Cash Flow$ 356.00K$ -133.00K$ -95.00K$ -113.00K$ 11.13M
Financing Cash Flow$ 175.85M$ 25.04M$ -14.70M$ 106.76M$ 44.78M
Currency in USD

Avalo Therapeutics Earnings and Revenue History

Avalo Therapeutics Debt to Assets

Avalo Therapeutics Cash Flow

Avalo Therapeutics Forecast EPS vs Actual EPS

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis